Vaccinations in older adults: Focus on pneumococcal, influenza and herpes zoster infections

Canadian Pharmacists Journal

Volumn 144, Issue 3, 2011, Pages 132-141

  Kau, Lang ^a   Sadowski, Cheryl A ^a   Hughes, Christine ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE;

CANADA; DRUG TOLERABILITY; ELDERLY CARE; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; PHARMACIST; PNEUMOCOCCAL INFECTION; REVIEW; VACCINATION;

EID: 79958026734     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.3821/1913-701X-144.3.132     Document Type: Review

References (65)

1. Statistics Canada. 2006 Census: age and sex. Available: www.statcan.gc.ca/daily-quotidien/070717/dq070717a-eng.htm (accessed June 22, 2010).
2. Kovaiou RD, Grubeck-Loebenstein B. Age-associated changes within CD4+ T cells. Immunol Lett 2006;107(1):8-14.
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with infuenza and respiratory syncytial virus in the United States. JAMA 2003;289(2):179-86.
4. Stuart B, Davidoff A, Lloyd J. Does infuenza vaccination of older adult Medicare benefciaries lower treatment costs for acute and chronic respiratory disease? Am J Geriatr Pharma-cother 2010;8(3):201-14.
5. Alberta College of Pharmacy. Guidelines and criteria for injection and immunization continuing education programs for Alberta pharmacists. 2007. Available: https://pharmacists.ab.ca/nCollege/resource.aspx?id=6054 (accessed July 18, 2010).
6. Ministry of Health Services. Ministry of Health News Release - October 21, 2009 (Injections/Vaccines/H1N1). 2009. Available: www.bcpharmacists.org/library/A-About_Us/A-8_Key_Initiatives/MOH-News_Release-2009HSERV0026-000515.pdf (accessed July 18, 2010).
7. New Brunswick Pharmaceutical Society. Administration of injections policy. 2009. Available: www.nbpharmacists.ca/LinkClick.aspx?fleticket=Z970wXBQQYc%3d&tabid=261&mid=695 (accessed July 18, 2010).
8. Immunization Action Coalition. States authorizing pharmacists to vaccinate. Available: http://www.immunize.org/laws/pharm.asp (accessed July 18, 2010).
9. Miazga EJ, Biesboer AN, Hayney MS. Updated recommendations for the use of pneumococcal polysaccharide vaccine. J Am Pharm Assoc 2010;50(2):321-23.
10. Vila-Córcoles A. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumo-coccal vaccination. J Intern Med 2009;266(5):432-44.
11. Statistics Canada. Deaths and mortality rate, by selected grouped causes, age group and sex, Canada, annual. Available: http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.pgm (accessed November 16, 2010).
12. Preventing pneumococcal disease: a Canadian consensus conference. Can Commun Dis Rep 1999;25(4):25-35.
13. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
14. Environics Research Group (prepared for Public Health Agency of Canada). Canadian adult national immunization coverage (adult NICS) survey - 2006: fnal report. Available: http://resources.cpha.ca/CCIAP/data/544e.pdf (accessed July 19, 2010).
15. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Can Com-mun Dis Rep 2002;28(ACS-2):1-32.
16. Public Health Agency of Canada. Canadian immunization guide. Seventh edition. Ottawa (ON): Public Health Agency of Canada; 2006:209-20, 267-76.
17. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006;43(7):860-8.
18. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneu-mococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348(18):1747-55.
19. Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with infuenza and 23-valent pneu-mococcal vaccines in elderly people: a 1-year follow-up. Vaccine 2003;21(25-26):3906-11.
20. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered infuenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17(20-21):2493-500.
21. Maruyama T, Taguchi O, Niederman MS, et al. Effcacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010;340:1004.
22. Koivula I, Sten M, Leinonen M, Makela PH. Clinical effcacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103(4):281-90.
23. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine effcacy. An evaluation of current recommendations. JAMA 1993;270(15):1826-31.
24. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351(9100):399-403.
25. Fisman DN, Abrutyn E, Spaude KA, et al. Prior pneumococ-cal vaccination is associated with reduced death, complications and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006;42(8):1093-101.
26. Alfageme I, Vazquez R, Reyes N, et al. Clinical effcacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61(3):189-95.
27. Mooney JD, Weir A, McMenamin J, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008;8:53.
28. Dominguez A, Salleras L, Fedson DS, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 2005;40(9):1250-7.
29. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004;23(2):132-8.
30. Benin AL, O'Brien KL, Watt JP, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococ-cal disease in Navajo adults. J Infect Dis 2003;188(1):81-9.
31. Cook IF, Pond D, Hartel G. Comparative reactogenicity and immunogenicity of 23-valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2007;25(25):4767-74.
32. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal infuenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-8).
33. Sanof Pasteur Ltd. INTANZA [product monograph]. Toronto (ON): Sanofi Pasteur Limited; 2010. Available: https://www.vaccineshoppecanada.com/document.cfm?fle=intanza_2010-05_en.pdf (accessed November 16, 2010).
34. AstraZeneca Canada Inc. FluMist. Available: http://fumist-canada.com/ (accessed August 10, 2010).
35. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on seasonal trivalent inactivated infuenza vaccine (TIV) for 2009-2010. Can Commun Dis Rep 2009;35(ACS-6):1-41. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-dcc-6/index-eng.php (accessed July 10, 2010).
36. Crocetti E, Arniani S, Bordoni F, et al. Effectiveness of infu-enza vaccination in the elderly in a community in Italy. Eur J Epidemiol 2001;17(2):163-8.
37. De Villiers PJ, Steele AD, Hiemstra LA, et al. Effcacy and safety of a live attenuated infuenza vaccine in adults 60 years of age and older. Vaccine 2009;28(1):228-34.
38. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual infuenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J 2009;30(2):209-16.
39. Nordin J, Mullooly J, Poblete S, et al. Infuenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York and Oregon: data from 3 health plans. J Infect Dis 2001;184(6):665-70.
40. Nichol KL, Nordin J, Mullooly J, et al. Infuenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348(14):1322-32.
41. Hara M, Sakamoto T, Tanaka K. Infuenza vaccine effectiveness among elderly persons living in the community during the 2003-2004 season. Vaccine 2008;26(50):6477-80.
42. Voordouw BC, van der Linden PD, Simonian S, et al. Infu-enza vaccination in community-dwelling elderly: impact on mortality and infuenza-associated morbidity. Arch Intern Med 2003;163(9):1089-94.
43. Spaude KA, Abrutyn E, Kirchner C, et al. Infuenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007;167(1):53-9.
44. Monto AS, Hornbuckle K, Ohmit SE. Infuenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001;154(2):155-60.
45. Looijmans-van den Akker I, Verheij TJ, Buskens E, et al. Clinical effectiveness of frst and repeat infuenza vaccination in adult and elderly diabetic patients. Diabetes Care 2006;29(8):1771-6.
46. Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revaccination against infuenza and mortality risk in community-dwelling elderly persons. JAMA 2004;292(17):2089-95.
47. Groenwold RH, Hoes AW, Hak E. Impact of infuenza vaccination on mortality risk among the elderly. Eur Resp J 2009;34(1):56-62.
48. Puig-Barbera J, Diez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit infuenza vaccine in preventing hospitalisations for cardiovascular disease, cere-brovascular disease and pneumonia in the elderly. Vaccine 2007;25(42):7313-21.
49. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993;270(16):1956-61.
50. Wang CS, Wang ST, Chou P. Effcacy and cost-effectiveness of infuenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine 2002;20(19-20):2494-9.
51. Govaert TM, Thijs CT, Masurel N, et al. The effcacy of infuenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994;272(21):1661-5.
52. Wang CS, Wang ST, Lai CT, et al. Impact of infuenza vaccination on major cause-specific mortality. Vaccine 2007;25(7):1196-203.
53. Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of infuenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004;190(1):1-10.
54. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127(2):305-14.
55. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84.
56. Betts RF. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 2007;57(6 Suppl):S143-7.
57. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization. Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010;36(ACS-1):1-19. Available: www.phac-aspc.gc.ca/publi-cat/ccdr-rmtc/10vol36/acs-1/index-eng.php (accessed July 27, 2010).
58. Euler GL, Lu P, Singleton JA. Vaccination coverage among US adults. National Immunization Survey - Adult, 2007. March 2008. Available: www.cdc.gov/vaccines/stats-surv/nis/downloads/nis-adult-summer-2007.pdf (accessed June 22, 2010).
59. Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007;25(11):2139-44.
60. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specifc immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197(6):825-35.
61. Trannoy E, Berger R, Holländer G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18(16):1700-6.
62. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010;152(9):545-54.
63. Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008;197(Suppl 2):S237-S241.
64. Van Amburgh JA, Waite NM, Hobson EH, Migden H. Improved infuenza vaccination rates in a rural population as a result of a pharmacist-managed immunization campaign. Pharmacotherapy 2001;21(9):1115-22.
65. Steyer TE, Ragucci KR, Pearson WS, Mainous AG. The role of pharmacists in the delivery of infuenza vaccinations. Vaccine 2004;22(8):1001-6.